
Business resources for Canadian pharmacists
As a trusted Canadian-owned pharmaceutical company, Apotex is proud to support pharmacists across Canada with tools and resources designed to strengthen your practice. We offer both business and practical resources, which are key building blocks to help you deliver exceptional pharmacy services and grow your business.
Our business and practice resources include:
The Apotex 360 Platform
Apotex 360 is an intuitive, modern digital platform serving as your all-in-one source for Apotex value-added programs, services, resources, and information. You can download the Apotex 360 app from the Apple Store or Google Play, or access the web version at www.apotex360.ca.
Pharmacists will find a wealth of valuable information, including:
- iPharmacist 360®: A quick, one-stop solution for medication, health, and clinical questions. Powered by Lexicomp™, an industry-leading provider of trusted drug and clinical information, this program helps you find reliable answers when you need them. Speak with your Apotex Sales Representative about accessing an annual subscription.
- Resources 360: Offers business tools like print-ready marketing materials to promote your pharmacy services, sales-boosting tips, and practice resources such as patient education pamphlets and instructional videos.
- News 360: Stay updated with daily news feeds covering national and provincial pharmacy industry developments across Canada.
- Apotex Products: A comprehensive listing of Apotex products and available strengths to support your pharmacy inventory and patient needs.
The Apotex Concierge Service
Pharmacy practice is evolving, and Apotex is here to help you adapt and thrive. Our dedicated Concierge Team connects you to a wide network of leading Canadian industry vendors and suppliers. Whether you need healthcare supplies, pharmacy renovation services, marketing expertise, or other support, we’ll help you find the right partners, so you can focus on delivering quality care to your patients.
Drug information support for Canadian healthcare professionals
DISpedia is Apotex's dedicated drug information service, created to support healthcare professionals with timely, accurate, and evidence-based information. Whether you're a pharmacist, physician, nurse, or other healthcare provider, our expert team is here to help — at no cost to you.
Our multidisciplinary team includes Canadian-licensed pharmacists, nurses, physicians, and medical students who are equipped to provide clear, unbiased responses to your drug- or product-related inquiries.
How we can help
Contact DISpedia for information related to:
- Apotex products and formulations
- General drug or disease-related questions
- Apotex programs and internal resources
- Special Access Program (SAP) inquiries
We’re committed to supporting clinical decisions with dependable, up-to-date information, so you can focus on delivering exceptional care.
Contact DISpedia
Hours of Operation:
Monday to Friday, 9:00 a.m. – 5:00 p.m. (EST)
Phone: 1-800-667-4708


ApoAssist


ApoSecure
Latest news
-
Oct 8, 2025
Apotex supports launch of home-based cancer care with $1.5M donation
Apotex is helping bring oncology care directly into patients' homes through a $1.5 million donation to Sunnybrook Foundation. The contribution supports the launch of Cancer Care at Home, a new initiative under the Odette Cancer Program that delivers timely cancer care where patients live.
-
Oct 7, 2025
Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment
Searchlight Pharma Inc.(“Searchlight”), Apotex Inc’s (“Apotex”) Branded Medicines Division today announced it has entered into a strategic licensing agreement securing exclusive Canadian rights to linzagolix, a once-daily oral treatment developed by Kissei Pharmaceutical Co., Ltd. Linzagolix belongs to a class of medicines called GnRH antagonists.
-
Jul 2, 2025
Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats
Apotex Inc., the Canadian-based global health company, today announced that Health Canada has approved Aflivu™ (aflibercept), a biosimilar to Eylea®, indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema secondary to central or branch retinal vein occlusion, treatment of diabetic macular edema, and treatment of myopic choroidal neovascularization.